Literature DB >> 10886044

Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate.

V K Sharma1, B Peyton, T Spears, J P Raufman, C W Howden.   

Abstract

BACKGROUND: Omeprazole and lansoprazole can be given in sodium bicarbonate as, respectively, simplified omeprazole suspension and simplified lansoprazole suspension. We previously found the antisecretory effect of omeprazole 20 mg given as simplified omeprazole suspension to be lower than with intact capsules. However, lansoprazole 30 mg as simplified lansoprazole suspension produced an effect similar to that seen with intact capsules. AIM: To evaluate the absorption of both drugs when given orally as capsules or as suspensions in sodium bicarbonate.
METHODS: In random order, we gave 5-day courses of omeprazole 20 mg and lansoprazole 30 mg as capsules and as suspensions in sodium bicarbonate to 12 healthy women. Serial blood samples were taken on days 1 and 5 of each course for pharmacokinetic measurements.
RESULTS: There was impairment of omeprazole absorption when given as simplified omeprazole suspension. Maximum plasma concentration and area under the concentration/time curve were lower with simplified omeprazole suspension than with omeprazole capsules (P=0.034 and 0.013, respectively, on day 5). No differences were found in lansoprazole absorption when simplified lansoprazole suspension was compared with its standard capsule formulation. Relative bioavailability of omeprazole from simplified omeprazole suspension compared to the capsule was 58.4% on day 5. The corresponding value for lansoprazole was 84.7%.
CONCLUSIONS: Simplified omeprazole suspension 20 mg does not supply adequate omeprazole for systemic absorption. Lansoprazole absorption from simplified lansoprazole suspension is maintained.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10886044     DOI: 10.1046/j.1365-2036.2000.00794.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  Management of Esophageal Strictures in Children.

Authors:  Norberto Rodriguez-Baez; John M. Andersen
Journal:  Curr Treat Options Gastroenterol       Date:  2003-10

2.  Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Kazuro Ikawa; Norifumi Morikawa; Susumu Tazuma
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

3.  Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems.

Authors:  Koen Boussery; Julie De Smet; Pieter De Cock; Saskia Vande Velde; Els Mehuys; Peter De Paepe; Jean Paul Remon; Jan F P Van Bocxlaer; Myriam Van Winckel
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

4.  Blue Rubber Bleb Nevus Syndrome.

Authors:  John M. Andersen
Journal:  Curr Treat Options Gastroenterol       Date:  2001-10

5.  Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects.

Authors:  Brian Grabowski; Ronald D Lee
Journal:  Clin Drug Investig       Date:  2012-05-01       Impact factor: 2.859

6.  Possible interethnic differences in omeprazole pharmacokinetics : comparison of Jordanian Arabs with other populations.

Authors:  Sireen Shilbayeh; Maha F Tutunji
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 7.  Pharmacokinetics of proton pump inhibitors in children.

Authors:  Catherine Litalien; Yves Théorêt; Christophe Faure
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

8.  Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment.

Authors:  Benjamin D Gold; James W Freston
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 9.  The use of proton pump inhibitors in children: a comprehensive review.

Authors:  Troy E Gibbons; Benjamin D Gold
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 10.  Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition.

Authors:  Joseph R Pisegna
Journal:  Crit Care Med       Date:  2002-06       Impact factor: 7.598

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.